AB
RAPP

Amalgamated Bank’s Rapport Therapeutics RAPP Stock Holding History

Amalgamated Bank’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-894
Closed -$27K – 2866
2025
Q4 		$27K Buy
894
+312
+54% +$8.63K ﹤0.01% 2006
2025
Q3 		$17K Hold
582
– – ﹤0.01% 2219
2025
Q2 		$7K Hold
582
– – ﹤0.01% 2614
2025
Q1 		$6K Buy
582
+265
+84% +$3.44K ﹤0.01% 2630
2024
Q4 		$6K Hold
317
– – ﹤0.01% 2696
2024
Q3 		$6K Buy
+317
New +$6.81K ﹤0.01% 2731

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Amalgamated Bank's RAPP Position: Q1 2026 in Review

Amalgamated Bank sold out of Rapport Therapeutics (RAPP) in Q1 2026, closing a stake of 894 shares — an estimated $27K sold.

Amalgamated Bank first reported a position in RAPP in Q3 2024 and held it in 6 quarters. The position peaked at $27K in Q4 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Amalgamated Bank reported no remaining Rapport Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 894 Rapport Therapeutics shares in Q1 2026, an estimated $27K.
  • Amalgamated Bank first reported a position in Rapport Therapeutics in Q3 2024 and held it in 6 quarters.
  • Amalgamated Bank's Rapport Therapeutics position peaked at $27K in Q4 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.